Tumor-Derived Extracellular Vesicles Breach the Intact Blood–Brain Barrier via Transcytosis
Boston Children's Hospital · Harvard University · +5 more institutions
Abstract
The restrictive nature of the blood–brain barrier (BBB) creates a major challenge for brain drug delivery with current nanomedicines lacking the ability to cross the BBB. Extracellular vesicles (EVs) have been shown to contribute to the progression of a variety of brain diseases including metastatic brain cancer and have been suggested as promising therapeutics and drug delivery vehicles. However, the ability of native tumor-derived EVs to breach the BBB and the mechanism(s) involved in this process remain unknown. Here, we demonstrate that tumor-derived EVs can breach the intact BBB in vivo, and by using state-of-the-art in vitro and in vivo models of the BBB, we have identified transcytosis as the mechanism…
Citation impact
- FWCI
- 20.16
- Percentile
- 100%
- References
- 61
Authors
10- GMGolnaz Morad
Boston Children's Hospital, Harvard University
- CVChristopher V. Carman
- EJElliott J. Hagedorn
Boston Children's Hospital, Howard Hughes Medical Institute, Harvard University, Dana-Farber Cancer Institute, Harvard Stem Cell Institute
- JRJulie R. Perlin
Boston Children's Hospital, Howard Hughes Medical Institute, Harvard University, Dana-Farber Cancer Institute, Harvard Stem Cell Institute
- LILeonard I. Zon
Boston Children's Hospital, Howard Hughes Medical Institute, Harvard University, Dana-Farber Cancer Institute, Harvard Stem Cell Institute
Topics & keywords
- Transcytosis
- Blood–brain barrier
- Transcellular
- In vivo
- Microvesicles
- Drug delivery
- Endocytic cycle
- Drug delivery to the brain
- Good health and well-being